Accessing the US Capital Markets from Outside the United States – A Primer for UK Life Sciences Companies

Latham partner Wesley Holmes joins LifeSci Advisors to discuss the UK life sciences eco-system, focusing on initial public offerings and alternative routes to going public.


Latham & Watkins, in partnership with LifeSci Advisors, is pleased to co-host a series of comprehensive panel discussions on topics that are of particular interest to European-based foreign private issuers and their advisors in the life sciences sector.

This session will focus strictly on the UK life sciences eco-system, and is intended to provide clarity around the legal, investment, and regulatory processes applicable to capital-raising activities in the United States. Topics will cover initial public offerings and alternative routes to going public, as well as what it takes to attract US investors and the benefits of listing in the US.


Michael Baldock, CFO, Abcam

Wesley Holmes, Life Sciences Corporate Partner, Latham & Watkins

Chris Maggos, Managing Director, Head of Europe, LifeSci Advisors

Nicholas Moore, Managing Director, Healthcare, Stifel

Jordan Saxe, Head of Healthcare, Listings & Capital Markets, Nasdaq


Please email to register your interest in attending this event.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.